The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals to develop two agentic AI assistants for ...
After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...
11don MSN
Legal questions swirl around FDA's new expedited drug program, including who should sign off
The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald ...
The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...
Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.
Management reiterated plans to initiate the REVEAL pivotal trial for TSHA-102, with the first patient dosing scheduled for the current quarter and additional enrollment expected across multiple sites.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results